Organization | inVentiv

inVentiv Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Princeton NJ United States (1984)

Status: Acquired by Syneos Health (2017)

Organization Overview

First Clinical Trial

2011

NCT01302405

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: inVentiv (0) Acquired (1)

idursulfase (elaprase) (1 trial)

Drugs in Phase 3 Trials (5)

Key: inVentiv (4) Acquired (1)

albumin (Human) (Plasbumin) (1 trial)

cat epidermis allergen (2 trials)

diazepam (valium) (3 trials)

givinostat (1 trial)

testosterone (delatestryl) (2 trials)

Drugs in Phase 2 Trials (17)

Key: inVentiv (14) Acquired (3)

131 iodine (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

bendamustine (treanda) (1 trial)

bortezomib (velcade) (1 trial)

ceftazidime (fortaz) (1 trial)

corticorelin ovine triflutate (acthrel) (1 trial)

drl-17822 (1 trial)

fospropofol (lusedra) (1 trial)

inactivated rabies vaccine (Imovax) (1 trial)

influenza vlp vaccine (1 trial)

nyx-2925 (1 trial)

prednisone (meticorten) (1 trial)

pri-724 (3 trials)

riluzole (rilutek) (2 trials)

sulbactam (unasyn) (1 trial)

sulfated oxysterol (1 trial)

syn023 (1 trial)

Drugs in Phase 1 Trials (21)

Key: inVentiv (6) Acquired (15)

antroquinonol (1 trial)

atenolol (tenormin) (1 trial)

bupropion (wellbutrin) (5 trials)

Cetilistat (oblean) (1 trial)

crizotinib (xalkori) (1 trial)

cyclobenzaprine (flexeril) (4 trials)

desloratadine (clarinex) (2 trials)

estradiol (progynon depot) (1 trial)

Filgrastim (neupogen) (1 trial)

Gusacitinib (1 trial)

kx0826 (1 trial)

letrozole (femara) (2 trials)

megestrol (megace) (1 trial)

mesalamine (rowasa) (1 trial)

moxifloxacin (avelox) (1 trial)

nateglinide (starlix) (2 trials)

nebivolol (bystolic) (1 trial)

oxytocin (syntocinon) (1 trial)

tranylcypromine (parnate) (1 trial)

ziprasidone (geodon) (2 trials)

zonisamide (Zonegran) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 1)

Amyotrophic Lateral Sclerosis (Phase 2)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Communicable Diseases (Phase 2)

Conjunctivitis (Phase 3)

Epilepsy (Phase 3)

Fibromyalgia (Phase 2)

Hemorrhage (Phase 1)

Hypogonadism (Phase 3)

Hypovolemia (Phase 3)

Infections (Phase 2)

Influenza, Human (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Myeloma (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Myofascial Pain Syndromes (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Neoplasms (Phase 1)

Postpartum Hemorrhage (Phase 1)

Rabies (Phase 2)

Respiratory Tract Diseases (Phase 2)

Respiratory Tract Infections (Phase 2)

RNA Virus Infections (Phase 2)

Sclerosis (Phase 2)

Ulcer (Phase 2)

Virus Diseases (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 55
# of Trial APIs: 44